New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

In Session
EE18-supplements-variety-regulations-getty.png

Following the rules: Five regulatory updates for the supplement industry

Join former FDA employee and current Faegre Baker Daniels counsel Jason Sapsin for a discussion about the current legal issues affecting the supplement industry.

“We all have a vested interest in maintaining and improving the public’s perception of the safety of dietary supplements. The industry does not run without consumer confidence.”

— Jason Sapsin, Counsel, Faegre Baker Daniels

Highlights:

  • With CBD products, you can be prosecuted at any time for any level of THC.
  • Probiotics have never been actually approved by the FDA for any therapeutic indication: the stronger your claims, the more likely you’ll be targeted.
  • New dietary ingredients (NDI) are probably the lowest level of concern; currently, there’s no enforcement.
  • The FDA has jurisdiction over roughly 20-25 cents of every dollar spent by every consumer in the U.S.—an enormous regulatory footprint.
  • Learn why Medicare Advantage may represent the single greatest opportunity for dietary supplement manufacturers and distributors in the last 5-10 years.

This session—The Supplement Round Table: Regulatory Updates—was recorded at Natural Products Expo East 2018. Click "download" to access the presentation slides.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish